The prognostic value of tumor mutation burden in -mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base.

BACKGROUND

Tumor mutation burden (TMB) is novel biomarker of promising predict value in prediction of immune checkpoint inhibitors (ICPis) in non-small cell lung cancer (NSCLC). However, the distribution of TMB in epidermal growth factor receptor ()-mutant advanced lung adenocarcinoma (LUAD) patients and the impact on overall survival (OS) time are not well demonstrated.

METHODS

Information regarding gene mutations and patients' survival time in advanced LUAD was downloaded from The Cancer Genome Atlas (TCGA) database. The diversity of TMB in different -mutant types was observed and the predicted value of TMB for OS as well as other co-mutations were analyzed. The diversity of TMB was also observed in another Chinese cohort of advanced LUAD patients.

RESULTS

The median TMB values of wild-type, other types of mutations, exon 19 deletions and L858R were 6.12, 5.66, 3.77 and 4.72, differences between wild-type and sensitive mutations (exon 19 deletion or L858R) were significant (P<0.001 and P<0.01). OS time of high TMB group was inferior to that of the low TMB group (24.03 months . not reached, P=0.0020). TMB and TP53 together will make more accurate prediction of OS in -mutant advanced LUAD patients. Distribution of TMB in another Chinese cohort had the same trend.

CONCLUSIONS

In advanced LUAD patients, TMB was lower in patients with -mutant group than wild group. TMB was a negative prognostic biomarker of OS in -mutant LUAD patients, especially when TP53 was mutated together.